when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Camzyos · news · pharmadog

← back to Camzyos

News mentioning Camzyos

18 stories

3dUnited Therapeutics' legal victory; BMS' Camzyos approved for kidsendpoints

Sep 2, 26Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial failsbiospace

Aug 31, 26ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsybiopharma dive

Aug 14, 26Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myersbiopharma dive

Aug 6, 26Braveheart pumps more life into biotech IPO market with $382M expected debutbiospace

Aug 6, 26Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengruifiercebiotech

Aug 6, 26Cardiac drug developer Braveheart banks more than $382M in IPObiopharma dive

Aug 5, 265 NextGen winners who went public this year (and which ones are hiring)biospace

Aug 3, 26An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.biopharma dive

Jul 31, 26Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsbiopharma dive

Jul 30, 26BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delaysbiospace

Jul 30, 26Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOsfiercebiotech

Jul 16, 26Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immunobiospace

Jul 15, 26Braveheart, Attovia join next wave of biotech IPOsbiopharma dive

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive

Jun 18, 26Kardigan extends biotech’s streak of big IPOs with $400M haulbiopharma dive

Jun 16, 26Edgewise heart drug passes key trial testbiopharma dive

May 5, 26Cytokinetics heart drug scores in closely watched trialbiopharma dive